These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19671763)

  • 21. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repurposing Ponatinib as a Potent Agent against
    Han Y; Gu Z; Wu J; Huang X; Zhou R; Shi C; Tao W; Wang L; Wang Y; Zhou G; Li J; Zhang Z; Sun S
    Theranostics; 2019; 9(7):1952-1964. PubMed ID: 31037149
    [No Abstract]   [Full Text] [Related]  

  • 23. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
    Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
    Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.
    Liang R; Wallace AR; Schadendorf D; Rubin BP
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):714-23. PubMed ID: 21595858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
    Smalley KS; Sondak VK; Weber JS
    Histol Histopathol; 2009 May; 24(5):643-50. PubMed ID: 19283671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.
    McKean M; Oba J; Ma J; Roth KG; Wang WL; Macedo MP; Carapeto FCL; Haydu LE; Siroy AE; Vo P; Hong DS; Eterovic AK; Patel KP; Bassett RL; Grimm EA; Lazar AJ; Woodman SE
    J Invest Dermatol; 2019 Mar; 139(3):728-731. PubMed ID: 30798855
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KIT and Melanoma: Biological Insights and Clinical Implications.
    Pham DDM; Guhan S; Tsao H
    Yonsei Med J; 2020 Jul; 61(7):562-571. PubMed ID: 32608199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
    Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
    Meng D; Carvajal RD
    Am J Clin Dermatol; 2019 Jun; 20(3):315-323. PubMed ID: 30707374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
    Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
    Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activate and resist: L576P-KIT in GIST.
    Conca E; Negri T; Gronchi A; Fumagalli E; Tamborini E; Pavan GM; Fermeglia M; Pierotti MA; Pricl S; Pilotti S
    Mol Cancer Ther; 2009 Sep; 8(9):2491-5. PubMed ID: 19723893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
    Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
    J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
    [No Abstract]   [Full Text] [Related]  

  • 36. Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model.
    Cullinane C; Natoli A; Hui Y; Conus N; Jackson S; Brüggen J; Manley PW; McArthur GA
    Mol Cancer Ther; 2010 May; 9(5):1461-8. PubMed ID: 20442311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
    Faderl S; Pal A; Bornmann W; Albitar M; Maxwell D; Van Q; Peng Z; Harris D; Liu Z; Hazan-Halevy I; Kantarjian HM; Estrov Z
    Cancer Res; 2009 May; 69(9):3910-7. PubMed ID: 19383925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.
    Posch C; Moslehi H; Sanlorenzo M; Green G; Vujic I; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
    Oncotarget; 2016 Jul; 7(29):45916-45925. PubMed ID: 27322141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients.
    Alexis JB; Martinez AE; Lutzky J
    Melanoma Res; 2005 Aug; 15(4):283-5. PubMed ID: 16034306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
    Guo J; Carvajal RD; Dummer R; Hauschild A; Daud A; Bastian BC; Markovic SN; Queirolo P; Arance A; Berking C; Camargo V; Herchenhorn D; Petrella TM; Schadendorf D; Sharfman W; Testori A; Novick S; Hertle S; Nourry C; Chen Q; Hodi FS
    Ann Oncol; 2017 Jun; 28(6):1380-1387. PubMed ID: 28327988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.